11.01.2013 Views

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

The dal-HEART Program:<br />

Dalcetrapib HDL Evaluation, Atherosclerosis,<br />

and Reverse Cholesterol Transport<br />

dal-VESSEL<br />

450 patients with<br />

CHD or CHD risk<br />

equivalent<br />

To evaluate the<br />

effect of<br />

dalcetrapib on<br />

endothelial<br />

function and BP,<br />

measured by<br />

FMD and ABPM<br />

dal-PLAQuE<br />

130 patients with<br />

CHD<br />

To evaluate the<br />

effect<br />

of dalcetrapib<br />

on<br />

inflammation,<br />

plaque<br />

size, and burden,<br />

measured by<br />

PET/CT and MRI<br />

scans<br />

dal-PLAQUE 2<br />

900 patients<br />

with CAD<br />

To evaluate the<br />

effect of<br />

dalcetrapib on<br />

CVD<br />

progression,<br />

assessed by<br />

IVUS<br />

and carotid Bmode<br />

ultrasound<br />

dal- ACUTE<br />

300 patients<br />

with ACS<br />

To evaluate<br />

the safety and<br />

efficacy of<br />

dalcetrapib in<br />

patients<br />

hospitalized for<br />

ACS. Treatment<br />

initiated within<br />

1 week a nd<br />

last for 20<br />

weeks<br />

ACS=acute coronary syndrome; FMD=flow-mediated dilation; ABPM=ambulatory blood pressure monitoring;<br />

CAD=coronary artery disease; IVUS=intravascular ultrasound; PET=positron emission tomography;<br />

CT=computed tomography; MRI=magnetic resonance<br />

Schwartz GG, et al. Amer. Heart J. 2009;158:896-901<br />

55

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!